106 related articles for article (PubMed ID: 25702260)
21. HER2
Hu HH; Wang SQ; Zhao H; Chen ZS; Shi X; Chen XB
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391024
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer.
Yang Y; Shao Y; Wang J; Cheng Q; Yang H; Li Y; Liu J; Zhou Y; Zhou Z; Wang M; Ji B; Yao J
Front Oncol; 2023; 13():1185240. PubMed ID: 37746295
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in chemotherapy for advanced gastric cancer.
Kim JG; Chung HY; Yu W
World J Gastrointest Oncol; 2010 Jul; 2(7):287-94. PubMed ID: 21160659
[TBL] [Abstract][Full Text] [Related]
24. Response to "Intrathecal trastuzumab: What else do we need to consider?" by Gao et al.
Le Rhun É; Oberkampf F; Bonneau C
Neuro Oncol; 2023 Feb; 25(2):420-421. PubMed ID: 36534958
[No Abstract] [Full Text] [Related]
25. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Gumusay O; Benekli M; Ekinci O; Baykara M; Ozet A; Coskun U; Demirci U; Uner A; Dursun A; Atak EY; Buyukberber S
Jpn J Clin Oncol; 2015 May; 45(5):416-21. PubMed ID: 25732909
[TBL] [Abstract][Full Text] [Related]
26. Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.
Ock CY; Lee KW; Kim JW; Kim JS; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Kim WH; Bang YJ; Oh DY
Clin Cancer Res; 2015 Jun; 21(11):2520-9. PubMed ID: 25712681
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
28. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.
Miura JT; Xiu J; Thomas J; George B; Carron BR; Tsai S; Johnston FM; Turaga KK; Gamblin TC
Cancer Biol Ther; 2015; 16(5):764-9. PubMed ID: 25778705
[TBL] [Abstract][Full Text] [Related]
29. HER2 expression status in diverse cancers: review of results from 37,992 patients.
Yan M; Schwaederle M; Arguello D; Millis SZ; Gatalica Z; Kurzrock R
Cancer Metastasis Rev; 2015 Mar; 34(1):157-64. PubMed ID: 25712293
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
31. Erratum to: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2016 May; 51(5):509-10. PubMed ID: 26956873
[No Abstract] [Full Text] [Related]
32. Identifying HER2 from serum-derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab-based therapy.
Li Q; Lv M; Lv L; Cao N; Zhao A; Chen J; Tang X; Luo R; Yu S; Zhou Y; Cui Y; Guo W; Liu T
Cancer Med; 2023 Feb; 12(4):4110-4124. PubMed ID: 36208025
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of CD166 and HER-2 in different types of gastric cancer.
Moradi L; Tajik F; Saeednejad Zanjani L; Panahi M; Gheytanchi E; Biabanaki ZS; Kazemi-Sefat GE; Hashemi F; Dehghan Manshadi M; Madjd Z
Clin Transl Oncol; 2024 Mar; 26(3):664-681. PubMed ID: 37537510
[TBL] [Abstract][Full Text] [Related]
34. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y; Kawazoe A; Lordick F; Janjigian YY; Shitara K
Nat Rev Clin Oncol; 2021 Aug; 18(8):473-487. PubMed ID: 33790428
[TBL] [Abstract][Full Text] [Related]
35. The extracellular domain of Her2 in serum as a biomarker of breast cancer.
Perrier A; Gligorov J; Lefèvre G; Boissan M
Lab Invest; 2018 Jun; 98(6):696-707. PubMed ID: 29491426
[TBL] [Abstract][Full Text] [Related]
36. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.
Shi HZ; Wang YN; Huang XH; Zhang KC; Xi HQ; Cui JX; Liu GX; Liang WT; Wei B; Chen L
World J Gastroenterol; 2017 Mar; 23(10):1836-1842. PubMed ID: 28348489
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
38. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab.
Wakatsuki T; Ishizuka N; Hironaka S; Minashi K; Kadowaki S; Goto M; Shoji H; Hirano H; Nakayama I; Osumi H; Ogura M; Chin K; Yamaguchi K; Takahari D
Int J Clin Oncol; 2024 Jun; 29(6):801-812. PubMed ID: 38589679
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer.
Yang M; Li Y; Kong L; Huang S; He L; Liu P; Mo S; Lu X; Lin X; Xiao Y; Shi D; Huang X; Chen B; Chen X; Ouyang Y; Li J; Lin C; Song L
J Clin Invest; 2023 Jul; 133(14):. PubMed ID: 37463446
[TBL] [Abstract][Full Text] [Related]
40. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
